Medicare Part D plans cover popular obesity drugs if they are used for an additional medically accepted purpose as approved ...

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.

Medicare released its next target list of 15 drugs to negotiate prices of, including Novo Nordisk's blockbuster GLP-1 drugs.

Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...

Taco Bell is re-upping its value menu game with the introduction of $5, $7 and $9 luxe cravings boxes, while TikTok is ...

Medicare drug plans can now cover Lilly’s obesity drug Zepbound for sleep apnea, according to CNBC. There’s a huge demand for the injection, and it opens the door for broader access to it ...

Investors scored big wins last year as the S&P 500, the Nasdaq, and the Dow Jones Industrial Average all climbed by double ...

Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...

Also in today’s edition: ‘no-show’ international student data and significant progress in Israel-Hamas ceasefire talks ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?